Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

Mark G. Lebwohl, Melinda Gooderham, Richard B. Warren, Lawrence F. Eichenfield, Jessica H. Rubens, Tracy Cardillo, Christopher Russo, Cynthia M. C. DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A. Hebert, Linda Stein Gold

Open source

DOI: 10.1007/s13555-026-01885-w
Published: 2026-08-28
Container: Dermatology and Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s13555-026-01885-w,
  title = {Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials},
  author = {Mark G. Lebwohl and Melinda Gooderham and Richard B. Warren and Lawrence F. Eichenfield and Jessica H. Rubens and Tracy Cardillo and Christopher Russo and Cynthia M. C. DeKlotz and Megan Miller-Kassamali and Luis Anaya Velarde and Ming-Chun Hsu and Shu Li and Ya-Wen Yang and Sarah Ofori and Robert Bissonnette and Jennifer Soung and Adelaide A. Hebert and Linda Stein Gold},
  year = {2026},
  journal = {Dermatology and Therapy},
  doi = {10.1007/s13555-026-01885-w},
  url = {https://doi.org/10.1007/s13555-026-01885-w}
}

RIS

TY  - JOUR
TI  - Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials
AU  - Mark G. Lebwohl
AU  - Melinda Gooderham
AU  - Richard B. Warren
AU  - Lawrence F. Eichenfield
AU  - Jessica H. Rubens
AU  - Tracy Cardillo
AU  - Christopher Russo
AU  - Cynthia M. C. DeKlotz
AU  - Megan Miller-Kassamali
AU  - Luis Anaya Velarde
AU  - Ming-Chun Hsu
AU  - Shu Li
AU  - Ya-Wen Yang
AU  - Sarah Ofori
AU  - Robert Bissonnette
AU  - Jennifer Soung
AU  - Adelaide A. Hebert
AU  - Linda Stein Gold
PY  - 2026
JO  - Dermatology and Therapy
DO  - 10.1007/s13555-026-01885-w
UR  - https://doi.org/10.1007/s13555-026-01885-w
ER  -

APA

Lebwohl, M. G., Gooderham, M., Warren, R. B., Eichenfield, L. F., Rubens, J. H., Cardillo, T., Russo, C., DeKlotz, C. M. C., Miller-Kassamali, M., Velarde, L. A., Hsu, M., Li, S., Yang, Y., Ofori, S., Bissonnette, R., Soung, J., Hebert, A. A., & Gold, L. S. (2026). Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01885-w

Source records

crossref · retrieved 2026-09-25T10:54:11.753Z